Kamada Sets 2026 Revenue Outlook on Plasma Therapy Demand
Kamada projected 2026 revenue of $200 million to $205 million and EBITDA of $50 million to $53 million. First-half revenue rose 13%, adjusted EBITDA increased 14%, and operating cash flow was nearly $18 million. The company cited Kedrab demand and a new plasma-supply agreement expected to generate about $17 million annually.
Kamada's first-half results put revenue near $100 million and EBITDA around $26 million, close to the midpoint of its full-year targets. The company also reported 21% earnings-per-share growth and almost $18 million in operating cash flow, with $70 million in cash at quarter-end.
Management outlined four growth areas: specialty plasma therapy sales, product distribution in Israel and MENA, third-party plasma supply, and acquisitions or licensing. Kedrab generated $54 million in 2025 sales, and a new three-year plasma agreement worth $50 million should add about $17 million yearly.
Kamada's outlook may matter to patients who depend on plasma-derived therapies, especially rabies immunoglobulin, because supply agreements and expanded distribution could affect availability. Investors and employees could benefit if growth and dividends continue, while plasma donors and partners may see changing demand. However, execution risks around acquisitions, supply, and market competition mean these effects are uncertain.